Kynard Adams
Family Medicine · Montgomery, ALNPI 1700873494
Payments from drug & device makers
Across 202 payments — averaging $19.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$687
- AstraZeneca$583
- AbbVie$368
- Lilly USA, LLC$305
- GSK$278
- Johnson & Johnson$237
- plus $1K from 22 others
What the payments were for
- Food & beverage$3,84699%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $687 |
| AstraZeneca | 28 | $583 |
| AbbVie(2 entities) | 13 | $368 |
| Lilly USA, LLC | 19 | $305 |
| GSK | 16 | $278 |
| Johnson & Johnson | 13 | $237 |
| Amgen(2 entities) | 12 | $196 |
| Amarin Pharma, Inc. | 7 | $194 |
| Sanofi-aventis U.S. LLC | 7 | $134 |
| Novartis | 6 | $115 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $114 |
| Bayer | 5 | $82 |
| Boehringer Ingelheim | 5 | $73 |
| Merck | 5 | $67 |
| Hikma Pharmaceuticals USA | 4 | $65 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $50 |
| Exact Sciences | 3 | $47 |
| Pfizer | 3 | $46 |
| Akcea Therapeutics, Inc. | 2 | $42 |
| Dexcom, Inc. | 2 | $34 |
| Sunovion Pharmaceuticals Inc. | 2 | $27 |
| Mylan Specialty L.p. | 2 | $26 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $14 |
| Eisai Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VRAYLAR$121
How this compares
$3,865 in reported general payments places this provider in the 75th percentile of 1,680 family medicine providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 45 | $58,398 |
| FarxigaDapagliflozin Propanediol | 46 | $44,654 |
| EliquisApixaban | 34 | $37,869 |
| JardianceEmpagliflozin | 28 | $34,629 |
| TrulicityDulaglutide | 22 | $32,168 |
| RybelsusSemaglutide | 19 | $30,904 |
| LinzessLinaclotide | 25 | $23,455 |
| JanuviaSitagliptin Phosphate | 14 | $17,735 |
| MyrbetriqMirabegron | 12 | $12,792 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $6,463 |
| Humalog Mix 75-25 KwikpenInsulin Lispro Protamin/Lispro | 18 | $5,215 |
| Atorvastatin Calcium | 175 | $2,196 |
| Esomeprazole Magnesium | 12 | $2,083 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $1,877 |
| Omeprazole | 92 | $1,868 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $687 | $89,30264 claims |
| AstraZenecaFarxiga | $583 | $44,65446 claims |
| PfizerEliquis | $46 | $37,86934 claims |
| Boehringer IngelheimJardiance | $73 | $34,62928 claims |
| Lilly USA, LLCTrulicity | $305 | $32,16822 claims |
| AbbVieLinzess | $368 | $23,45525 claims |
| MerckJanuvia | $67 | $17,73514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,680 family medicine providers in Alabama.
Other family medicine in Montgomery
- Thavatchai ChamnongchareonwongMontgomery$18K
- Michael VaughnBirmingham$9.9M
- William NixonGuntersville$7.1M
- Randall QuinnCullman$5.4M
- Matthew CaldwellAthens$4.1M
- Michael CarterHuntsville$3.4M
- Howard RubensteinSaraland$3.3M
- Randle MiddletonHuntsville$3.3M
- Aaron KarrSheffield$3.1M
- Nidal MorrarFoley$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.